Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study...
May 07, 2025 07:00 ET | Source: Amarin Corporation plc

Amarin Reports First Quarter 2025 Financial Results

-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global...
May 07, 2025 07:00 ET | Source: Lantheus Holdings, Inc.

Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share...
May 07, 2025 04:28 ET | Source: Research and Markets

Gas Detection Equipment Market Review 2021-2024 and Forecast 2025-2030: Infrared Sensor-Based Gas Detection Equipment Leads Market, While Semiconductor Sensors See Fastest Growth at 9.7% CAGR

Dublin, May 07, 2025 (GLOBE NEWSWIRE) -- The "Gas Detection Equipment Market - Detector Types, Sensor Technologies and Applications" report has been added to ResearchAndMarkets.com's offering.The...
May 07, 2025 01:00 ET | Source: VALNEVA

Valneva publie ses résultats financiers du premier trimestre 2025 et fait un point sur son activité

Chiffre d’affaires de 49,2 millions d’euros contre 32,8 millions d’euros au premier trimestre 2024Trésorerie et équivalents de trésorerie de 153,0 millions d’euros à fin mars 2025 Poursuite des...
May 06, 2025 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with...
May 06, 2025 16:01 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670...
May 06, 2025 06:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Reports First Quarter 2025 Financial Results

– Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – – Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y to...
May 05, 2025 08:10 ET | Source: SNS Insider pvt ltd

Medical Writing Market Size to Hit USD 10.5 Billion by 2032, Fueled by Surging Demand for Regulatory and Clinical Documentation – SNS Insider

Austin, May 05, 2025 (GLOBE NEWSWIRE) -- Global Medical Writing Market Growth Analysis & Trends: According to the latest research from SNS Insider, the Medical Writing Market size was valued at...
May 05, 2025 07:49 ET | Source: Teva Pharmaceutical Industries Ltd

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April...